CAPR vs. AHCO, NEOG, BLFS, PAHC, INMD, KMTS, CBLL, EOLS, OMI, and MRVI
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include AdaptHealth (AHCO), Neogen (NEOG), BioLife Solutions (BLFS), Phibro Animal Health (PAHC), InMode (INMD), Kestra Medical Technologies (KMTS), CeriBell (CBLL), Evolus (EOLS), Owens & Minor (OMI), and Maravai LifeSciences (MRVI). These companies are all part of the "med products" industry.
Capricor Therapeutics vs. Its Competitors
AdaptHealth (NASDAQ:AHCO) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.
82.7% of AdaptHealth shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 1.6% of AdaptHealth shares are held by company insiders. Comparatively, 10.5% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
AdaptHealth presently has a consensus target price of $13.40, indicating a potential upside of 40.31%. Capricor Therapeutics has a consensus target price of $33.75, indicating a potential upside of 202.69%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than AdaptHealth.
AdaptHealth has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
AdaptHealth has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
In the previous week, Capricor Therapeutics had 21 more articles in the media than AdaptHealth. MarketBeat recorded 24 mentions for Capricor Therapeutics and 3 mentions for AdaptHealth. AdaptHealth's average media sentiment score of 0.63 beat Capricor Therapeutics' score of 0.26 indicating that AdaptHealth is being referred to more favorably in the media.
AdaptHealth has a net margin of 2.63% compared to Capricor Therapeutics' net margin of -181.71%. AdaptHealth's return on equity of 6.96% beat Capricor Therapeutics' return on equity.
Summary
AdaptHealth beats Capricor Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 6/29/2025 by MarketBeat.com Staff
Buy CAPR Stock Free CAPR Stock Alerts